Literature DB >> 28251077

The effects of anti-vascular endothelial growth factor agents on human retinal pigment epithelial cells under high glucose conditions.

Jong Rok Oh1, Jung Woo Han1, Yoon Kyung Kim1, Young-Hoon Ohn1, Tae Kwann Park1.   

Abstract

AIM: To investigate the effects of high glucose levels and anti-vascular endothelial growth factor (VEGF) agents (bevacizumab, ranibizumab and aflibercept) on retinal pigment epithelium (RPE) cells.
METHODS: ARPE-19 cells were cultured at different glucose levels (5.5 mmol/L, 25 mmol/L, and 75 mmol/L). Cell viability was evaluated by MTT assay at 3d after treatment with D-glucose. Cell migration ability was measured by wound healing assay at 3d. A cell death detection kit was used to assess apoptosis at 3 and 14d. Cell proliferation was assessed by EdU assay at 3d. The culture medium was treated with anti-VEGF agents at clinically relevant concentrations. The experiment was then repeated at a different glucose level.
RESULTS: The viability and migration of ARPE-19 cells were significantly decreased in the presence of 75 mmol/L as compared to 5.5 mmol/L glucose. The percentage of TUNEL-positive cells was significantly increased and the proliferative potential was decreased with 75 mmol/L compared to 5.5 mmol/L glucose. There were no significant differences in the results between 25 mmol/L and 5.5 mmol/L glucose. In the presence of 75 mmol/L glucose, the groups treated with anti-VEGF showed decreased cell viability and proliferation and increased apoptosis. However, there were no significant differences between the anti-VEGF groups.
CONCLUSION: High glucose level decreases the viability, wound healing ability, and proliferation of RPE cells, while increasing apoptosis. Furthermore, anti-VEGF agents interfered with the physiological functions of RPE cells under high-glucose conditions, accompanied by decreases in cell viability and proliferation.

Entities:  

Keywords:  anti-vascular endothelial growth factor; high glucose; retinal pigment epithelium

Year:  2017        PMID: 28251077      PMCID: PMC5313541          DOI: 10.18240/ijo.2017.02.04

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  26 in total

1.  Vectorial release of matrix metalloproteinases (MMPs) from porcine RPE-choroid explants following selective retina therapy (SRT): towards slowing the macular ageing process.

Authors:  F Treumer; A Klettner; J Baltz; A A Hussain; Y Miura; R Brinkmann; J Roider; J Hillenkamp
Journal:  Exp Eye Res       Date:  2012-02-22       Impact factor: 3.467

2.  VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.

Authors:  Yoko Miura; Alexa Klettner; Johann Roider
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-30       Impact factor: 4.799

3.  Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway.

Authors:  Lu Cai; Wei Li; Guangwu Wang; Luping Guo; Youchun Jiang; Y James Kang
Journal:  Diabetes       Date:  2002-06       Impact factor: 9.461

4.  Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.

Authors:  S Doganay; C Evereklioglu; H Er; Y Türköz; A Sevinç; N Mehmet; H Savli
Journal:  Eye (Lond)       Date:  2002-03       Impact factor: 3.775

5.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

6.  Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.

Authors:  Sebastian Thaler; Michal Fiedorowicz; Tomasz J Choragiewicz; Sylvia Bolz; Ayseguel Tura; Sigrid Henke-Fahle; Efdal Yoeruek; Eberhart Zrenner; Karl-Ulrich Bartz-Schmidt; Focke Ziemssen; Frank Schuettauf
Journal:  Acta Ophthalmol       Date:  2010-05-14       Impact factor: 3.761

7.  Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.

Authors:  Alexa Klettner; Friederike Möhle; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-19       Impact factor: 3.117

8.  Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.

Authors:  Sven Schnichels; Ulrike Hagemann; Kai Januschowski; Johanna Hofmann; Karl-Ulrich Bartz-Schmidt; Peter Szurman; Martin S Spitzer; Sabine Aisenbrey
Journal:  Br J Ophthalmol       Date:  2013-05-17       Impact factor: 4.638

9.  Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis.

Authors:  Alexa Klettner; Nihat Tahmaz; Michaela Dithmer; Elisabeth Richert; Johann Roider
Journal:  Br J Ophthalmol       Date:  2014-07-17       Impact factor: 4.638

10.  The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

View more
  4 in total

1.  Essential Role of mTOR Signaling in Human Retinal Pigment Epithelial Cell Regeneration After Laser Photocoagulation.

Authors:  Sanjar Batirovich Madrakhimov; Jin Young Yang; Ha Yan Park; Tae Kwann Park
Journal:  Lasers Med Sci       Date:  2018-11-29       Impact factor: 3.161

2.  Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells.

Authors:  Patrick R Merz; Nina Röckel; Seda Ballikaya; Gerd U Auffarth; Ingo Schmack
Journal:  BMC Ophthalmol       Date:  2018-12-11       Impact factor: 2.209

3.  The Efficacy of Single-Dose Intravitreal Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-VEGF Therapy: Real-Life Results.

Authors:  Mert Simsek; Mehmet Citirik; Serdar Ozates; Kemal Tekin; Dilara Ozkoyuncu
Journal:  Beyoglu Eye J       Date:  2020-02-19

4.  Kinsenoside Ameliorates Oxidative Stress-Induced RPE Cell Apoptosis and Inhibits Angiogenesis via Erk/p38/NF-κB/VEGF Signaling.

Authors:  Xu Luo; Shengjie Gu; Yujiao Zhang; Jianhong Zhang
Journal:  Front Pharmacol       Date:  2018-03-20       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.